Data availability<\/h2>\n
The accession numbers for the RNA-seq dataset in this study is GSE223805<\/a>(ref. 55<\/a><\/sup>). The GRCh38\/hg38 human reference genome is publicly available. Key plasmids, Cas9-T6N and Cas12a-T8N have been deposited at Addgene (plasmid ID, 199604\u2013199605). Source data<\/a> are provided with this paper, including unprocessed Western blots.<\/p>\n<\/div>\n Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature<\/i> 578<\/b>, 229\u2013236 (2020).<\/p>\n Article<\/a>\u00a0 Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR\u2013Cas9 for genome engineering. Cell<\/i> 157<\/b>, 1262\u20131278 (2014).<\/p>\n Article<\/a>\u00a0 Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell<\/i> 168<\/b>, 20\u201336 (2017).<\/p>\n Article<\/a>\u00a0 June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science<\/i> 359<\/b>, 1361\u20131365 (2018).<\/p>\n Article<\/a>\u00a0 Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer<\/i> 8<\/b>, 299\u2013308 (2008).<\/p>\n Article<\/a>\u00a0 Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science<\/i> 367<\/b>, eaba7365 (2020).<\/p>\n Article<\/a>\u00a0 Atsavapranee, E. S., Billingsley, M. M. & Mitchell, M. J. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. EBioMedicine<\/i> 67<\/b>, 103354 (2021).<\/p>\n Article<\/a>\u00a0 Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov.<\/i> 16<\/b>, 387\u2013399 (2017).<\/p>\n Article<\/a>\u00a0 Chen, Z. et al. In vivo CD8+<\/sup> T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell<\/i> 184<\/b>, 1262\u20131280 (2021).<\/p>\n<\/li>\n Dong, M. B. et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell<\/i> 178<\/b>, 1189\u20131204 (2019).<\/p>\n<\/li>\n Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature<\/i> 576<\/b>, 471\u2013476 (2019).<\/p>\n Article<\/a>\u00a0 Huang, H. et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+<\/sup> T-cell fate decisions. Cell<\/i> 184<\/b>, 1245\u20131261 (2021).<\/p>\n<\/li>\n LaFleur, M. W. et al. A CRISPR\u2013Cas9 delivery system for in vivo screening of genes in the immune system. Nat. Commun.<\/i> 10<\/b>, 1668 (2019).<\/p>\n<\/li>\n Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol.<\/i> 33<\/b>, 73\u201380 (2015).<\/p>\n<\/li>\n Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res.<\/i> 24<\/b>, 1020\u20131027 (2014).<\/p>\n Article<\/a>\u00a0 Staahl, B. T. et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol.<\/i> 35<\/b>, 431\u2013434 (2017).<\/p>\n Article<\/a>\u00a0 Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T. Y. & Pellois, J. P. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals (Basel)<\/i> 5<\/b>, 1177\u20131209 (2012).<\/p>\n Article<\/a>\u00a0 Heitz, F., Morris, M. C. & Divita, G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol.<\/i> 157<\/b>, 195\u2013206 (2009).<\/p>\n Article<\/a>\u00a0 Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control. Release<\/i> 151<\/b>, 220\u2013228 (2011).<\/p>\n Article<\/a>\u00a0 Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell<\/i> 55<\/b>, 1189\u20131193 (1988).<\/p>\n Article<\/a>\u00a0 Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med.<\/i> 10<\/b>, 310\u2013315 (2004).<\/p>\n Article<\/a>\u00a0 Wherry, E. J. T cell exhaustion. Nat. Immunol.<\/i> 12<\/b>, 492\u2013499 (2011).<\/p>\n Article<\/a>\u00a0 Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol.<\/i> 15<\/b>, 486\u2013499 (2015).<\/p>\n Article<\/a>\u00a0 Kurachi, M. et al. Optimized retroviral transduction of mouse T cells for in vivo<\/i> assessment of gene function. Nat. Protoc.<\/i> 12<\/b>, 1980\u20131998 (2017).<\/p>\n<\/li>\n Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature<\/i> 439<\/b>, 682\u2013687 (2006).<\/p>\n Article<\/a>\u00a0 Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science<\/i> 348<\/b>, 56\u201361 (2015).<\/p>\n Article<\/a>\u00a0 Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+<\/sup> T cells. J. Exp. Med.<\/i> 212<\/b>, 1125\u20131137 (2015).<\/p>\n Article<\/a>\u00a0 Gier, R. A. et al. High-performance CRISPR\u2013Cas12a genome editing for combinatorial genetic screening. Nat. Commun.<\/i> 11<\/b>, 3455 (2020).<\/p>\n Article<\/a>\u00a0 Kleinstiver, B. P. et al. Engineered CRISPR\u2013Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat. Biotechnol.<\/i> 37<\/b>, 276\u2013282 (2019).<\/p>\n Article<\/a>\u00a0 DeWeirdt, P. C. et al. Optimization of AsCas12a for combinatorial genetic screens in human cells. Nat. Biotechnol.<\/i> 39<\/b>, 94\u2013104 (2021).<\/p>\n Article<\/a>\u00a0 Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR\u2013Cas system. Cell<\/i> 163<\/b>, 759\u2013771 (2015).<\/p>\n Article<\/a>\u00a0 Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res.<\/i> 23<\/b>, 2255\u20132266 (2017).<\/p>\n Article<\/a>\u00a0 Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature<\/i> 543<\/b>, 113\u2013117 (2017).<\/p>\n Article<\/a>\u00a0 Weissman, I. L. & Shizuru, J. A. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood<\/i> 112<\/b>, 3543\u20133553 (2008).<\/p>\n Article<\/a>\u00a0 Grevet, J. D. et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science<\/i> 361<\/b>, 285\u2013290 (2018).<\/p>\n Article<\/a>\u00a0 Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N. Engl. J. Med.<\/i> 384<\/b>, 252\u2013260 (2021).<\/p>\n Article<\/a>\u00a0 Bauer, D. E. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science<\/i> 342<\/b>, 253\u2013257 (2013).<\/p>\n Article<\/a>\u00a0 Qin, K. et al. Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells. Nat. Genet.<\/i> 54<\/b>, 874\u2013884 (2022).<\/p>\n Article<\/a>\u00a0 Shmakov, S. et al. Diversity and evolution of class 2 CRISPR-Cas systems. Nat. Rev. Microbiol.<\/i> 15<\/b>, 169\u2013182 (2017).<\/p>\n Article<\/a>\u00a0 Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet.<\/i> 19<\/b>, 770\u2013788 (2018).<\/p>\n Article<\/a>\u00a0 Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature<\/i> 576<\/b>, 149\u2013157 (2019).<\/p>\n Article<\/a>\u00a0 Strecker, J. et al. RNA-guided DNA insertion with CRISPR-associated transposases. Science<\/i> 365<\/b>, 48\u201353 (2019).<\/p>\n Article<\/a>\u00a0 Yarnall, M. T. N. et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol.<\/i> (in press).<\/p>\n<\/li>\n Tou, C. J., Orr, B. & Kleinstiver, B. P. Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases. Nat. Biotechnol.<\/i> (in press).<\/p>\n<\/li>\n Durrant, M. G. et al. Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome. Nat. Biotechnol.<\/i> (in press).<\/p>\n<\/li>\n Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science<\/i> 354<\/b>, 1160\u20131165 (2016).<\/p>\n Article<\/a>\u00a0 Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a\/C2c2. Science<\/i> 356<\/b>, 438\u2013442 (2017).<\/p>\n Article<\/a>\u00a0 Cao, Z. et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Mol Cell<\/i> 81<\/b>, 3604\u20133622 (2021).<\/p>\n<\/li>\n Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther.<\/i> 17<\/b>, 1453\u20131464 (2009).<\/p>\n<\/li>\n Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics<\/i> 29<\/b>, 15\u201321 (2013).<\/p>\n Article<\/a>\u00a0 Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.<\/i> 43<\/b>, e47 (2015).<\/p>\n Article<\/a>\u00a0 Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol.<\/i> 37<\/b>, 224\u2013226 (2019).<\/p>\n Article<\/a>\u00a0 Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res.<\/i> 42<\/b>, e168 (2014).<\/p>\n Article<\/a>\u00a0 Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med.<\/i> 25<\/b>, 776\u2013783 (2019).<\/p>\n Article<\/a>\u00a0 Zhang, Z. et al. Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. NCBI. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE223805<\/a> (2023).<\/p>\n<\/li>\n<\/ol>\n Download references<\/a><\/p>\n<\/div>\n<\/div>\n We thank M. Szurgot and R. Marmorstein (Department of Biochemistry and Biophysics, University of Pennsylvania) for sharing the protease ULP1 expression vector and purification protocol. We also thank the staff at the Flow Cytometry Core Laboratory of Children\u2019s Hospital of Philadelphia. G.A.B. acknowledges NIH\/NHLBI (R01-HL119479). R.M.K. acknowledges NIH (R01-GM138908). E.J.W. acknowledges support from the NIH (AI105343, AI082630, AI108545, AI155577, AI149680 and U19AI082630), funding from the Allen Institute for Immunology and the Parker Institute for Cancer Immunotherapy. Work in the Wherry lab is supported by the Parker Institute for Cancer Immunotherapy. S.L.B. acknowledges NIH\/NCI (R35-CA263922). J.S. acknowledges NIH\/NCI (R01-CA258904).<\/p>\n<\/div>\n Epigenetics Institute, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Zhen Zhang,\u00a0Diqiu Ren,\u00a0Kunhua Qin,\u00a0Sierra M. Collins,\u00a0Hua Huang,\u00a0Chad A. Komar,\u00a0Peter F. Bailer,\u00a0Gerd A. Blobel,\u00a0Rahul M. Kohli,\u00a0Shelley L. Berger\u00a0&\u00a0Junwei Shi<\/p>\n<\/li>\n Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Zhen Zhang,\u00a0Sierra M. Collins,\u00a0Hua Huang\u00a0&\u00a0Shelley L. Berger<\/p>\n<\/li>\n Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Amy E. Baxter,\u00a0Zeyu Chen,\u00a0Hua Huang\u00a0&\u00a0E. John Wherry<\/p>\n<\/li>\n Institute for Immunology and Immune Health, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Amy E. Baxter,\u00a0Zeyu Chen\u00a0&\u00a0E. John Wherry<\/p>\n<\/li>\n Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Diqiu Ren,\u00a0Chad A. Komar\u00a0&\u00a0Junwei Shi<\/p>\n<\/li>\n Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Diqiu Ren,\u00a0Chad A. Komar\u00a0&\u00a0Junwei Shi<\/p>\n<\/li>\n Division of Hematology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA<\/p>\n Kunhua Qin\u00a0&\u00a0Gerd A. Blobel<\/p>\n<\/li>\n Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Peter F. Bailer,\u00a0Jared B. Parker\u00a0&\u00a0Rahul M. Kohli<\/p>\n<\/li>\n Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n Peter F. Bailer\u00a0&\u00a0Rahul M. Kohli<\/p>\n<\/li>\n Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA<\/p>\n E. John Wherry<\/p>\n<\/li>\n<\/ol>\n Z.Z., E.J.W., S.L.B. and J.S. conceived and developed the Peptide-Assisted Genome Editing (PAGE) approach and designed the research. Z.Z., A.E.B., D.R., K.Q., Z.C., S.M., H.H., C.A.K., P.F.B. and J.B.P. performed experiments and analyzed the data. G.A.B., R.M.K., E.J.W., S.L.B. and J.S. supervised the research. Z.Z. and J.S. drafted the manuscript. Z.Z., A.E.B., G.A.B., R.M.K., E.J.W., S.L.B. and J.S. reviewed and edited the manuscript with input from all authors. All authors read and approved the final manuscript.<\/p>\n Correspondence to Z.Z., A.E.B., Z.C., J.B.P., R.M.K., E.J.W., S.L.B. and J.S. through the University of Pennsylvania have filed a patent application on aspects of this work. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported this study. E.J.W. is an advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences. R.M.K. is on the Scientific Advisory Board for Life Edit, Inc.<\/p>\n<\/p><\/div>\n<\/div>\n Nature Biotechnology<\/i> thanks Meisam Kararoudi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.<\/p>\n<\/p><\/div>\n<\/div>\n Publisher\u2019s note<\/b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.<\/p>\n<\/div>\n Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.<\/p>\nReferences<\/h2>\n
\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\nAcknowledgements<\/h2>\n
Author information<\/h2>\n
Authors and Affiliations<\/h3>\n
\n
Contributions<\/h3>\n
Corresponding authors<\/h3>\n
\n E. John Wherry<\/a>, Shelley L. Berger<\/a> or Junwei Shi<\/a>.<\/p>\n<\/div>\n<\/div>\nEthics declarations<\/h2>\n
Competing interests<\/h3>\n
Peer review<\/h2>\n
Peer review information<\/h3>\n
Additional information<\/h2>\n
Supplementary information<\/h2>\n<\/div>\n
Source data<\/h2>\n<\/div>\n
Rights and permissions<\/h2>\n